Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials

Christopher E. Brightling; Mina Gaga; Hiromasa Inoue; Jing Li; Jorge Maspero; Sally Wenzel; Samopriyo Maitra; David Lawrence; Florian Brockhaus; Thomas Lehmann; Caterina Brindicci; Barbara Knorr; Eugene R. Bleecker

doi:10.1016/S2213-2600(20)30412-4

Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials

Christopher E. Brightling
, Mina Gaga
, Hiromasa Inoue
, Jing Li
, Jorge Maspero
, Sally Wenzel
, Samopriyo Maitra
, David Lawrence
, Florian Brockhaus
, Thomas Lehmann
, Caterina Brindicci
, Barbara Knorr
, Eugene R. Bleecker

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	43-56
Number of pages	14
Journal	The Lancet Respiratory Medicine
Volume	9
Issue number	1
DOIs	https://doi.org/10.1016/S2213-2600(20)30412-4
State	Published - Jan 2021
Externally published	Yes

ASJC Scopus Subject Areas

Pulmonary and Respiratory Medicine

Keywords

Double-Blind Method
Indoleacetic Acids/adverse effects
Humans
Middle Aged
Male
Treatment Outcome
Asthma/drug therapy
Hospitalization
Pyridines/adverse effects
Female
Anti-Asthmatic Agents/adverse effects
Leukocyte Count
Eosinophils

Access to Document

10.1016/S2213-2600(20)30412-4

OpenUrl availability

Full text

Cite this

Brightling, C. E., Gaga, M., Inoue, H., Li, J., Maspero, J., Wenzel, S., Maitra, S., Lawrence, D., Brockhaus, F., Lehmann, T., Brindicci, C., Knorr, B., & Bleecker, E. R. (2021). Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. The Lancet Respiratory Medicine, 9(1), 43-56. https://doi.org/10.1016/S2213-2600(20)30412-4

Brightling, CE, Gaga, M, Inoue, H, Li, J, Maspero, J, Wenzel, S, Maitra, S, Lawrence, D, Brockhaus, F, Lehmann, T, Brindicci, C, Knorr, B & Bleecker, ER 2021, 'Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials', The Lancet Respiratory Medicine, vol. 9, no. 1, pp. 43-56. https://doi.org/10.1016/S2213-2600(20)30412-4

@article{79a63cef910140ac88c30c62a5f43694,

title = "Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials",

keywords = "Double-Blind Method, Indoleacetic Acids/adverse effects, Humans, Middle Aged, Male, Treatment Outcome, Asthma/drug therapy, Hospitalization, Pyridines/adverse effects, Female, Anti-Asthmatic Agents/adverse effects, Leukocyte Count, Eosinophils",

author = "Brightling, \{Christopher E.\} and Mina Gaga and Hiromasa Inoue and Jing Li and Jorge Maspero and Sally Wenzel and Samopriyo Maitra and David Lawrence and Florian Brockhaus and Thomas Lehmann and Caterina Brindicci and Barbara Knorr and Bleecker, \{Eugene R.\}",

year = "2021",

month = jan,

doi = "10.1016/S2213-2600(20)30412-4",

language = "English",

volume = "9",

pages = "43--56",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

number = "1",

}

TY - JOUR

T1 - Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2)

T2 - two phase 3 randomised controlled trials

AU - Brightling, Christopher E.

AU - Gaga, Mina

AU - Inoue, Hiromasa

AU - Li, Jing

AU - Maspero, Jorge

AU - Wenzel, Sally

AU - Maitra, Samopriyo

AU - Lawrence, David

AU - Brockhaus, Florian

AU - Lehmann, Thomas

AU - Brindicci, Caterina

AU - Knorr, Barbara

AU - Bleecker, Eugene R.

PY - 2021/1

Y1 - 2021/1

KW - Double-Blind Method

KW - Indoleacetic Acids/adverse effects

KW - Humans

KW - Middle Aged

KW - Male

KW - Treatment Outcome

KW - Asthma/drug therapy

KW - Hospitalization

KW - Pyridines/adverse effects

KW - Female

KW - Anti-Asthmatic Agents/adverse effects

KW - Leukocyte Count

KW - Eosinophils

UR - https://www.scopus.com/pages/publications/85092238266

UR - https://www.scopus.com/pages/publications/85092238266#tab=citedBy

U2 - 10.1016/S2213-2600(20)30412-4

DO - 10.1016/S2213-2600(20)30412-4

M3 - Article

C2 - 32979986

AN - SCOPUS:85092238266

SN - 2213-2600

VL - 9

SP - 43

EP - 56

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 1

ER -

Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials

ASJC Scopus Subject Areas

Keywords

Access to Document

OpenUrl availability

Other files and links

Cite this